Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis.

Oncogene - 8 Jan 2009

Tamura Y, Simizu S, Muroi M, Takagi S, Kawatani M, Watanabe N, Osada H

Abstract excerpt

Bcl-x(L), an anti-apoptotic Bcl-2 family member protein, contributes to the resistance against chemotherapies such as tubulin-binder treatment in many human tumors. Although Bcl-x(L) is phosphorylated after tubulin-binder treatment, the role of the phosphorylation and its responsible kinase(s) are poorly understood. Here, we identified Plk1 (polo-like kinase 1) as a Bcl-x(L) kinase. Same location of Bcl-x(L) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to bcl-X Protein
Share to Cell Cycle Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polo-Like Kinase 1

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Pyrones

Share to Serine

Source

Identifiers

PMID: 18820703
DOI: 10.1038/onc.2008.368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis.PMID 18820703Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy.Semantic proximity Read ↗

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read ↗

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentSemantic proximity Read ↗

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Semantic proximity Read ↗

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read ↗

Polo-Like Kinases (Plks), a Key Regulator of Cell Cycle and New Potential Target for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.